nejmepoetinalfa in critically ill patients(blue slide set)
DESCRIPTION
TRANSCRIPT
![Page 1: Nejmepoetinalfa In Critically Ill Patients(Blue Slide Set)](https://reader035.vdocuments.site/reader035/viewer/2022062613/54559bf9af79595d048b5255/html5/thumbnails/1.jpg)
Presentation of NEJM Article on Efficacy & Safety of Epoetin Alfa in Critically Ill Patients
William C Lambert, M.D.
![Page 2: Nejmepoetinalfa In Critically Ill Patients(Blue Slide Set)](https://reader035.vdocuments.site/reader035/viewer/2022062613/54559bf9af79595d048b5255/html5/thumbnails/2.jpg)
Original Article Efficacy and Safety of Epoetin Alfa in Critically Ill
Patients
Howard L. Corwin, M.D., Andrew Gettinger, M.D., Timothy C. Fabian, M.D., Addison May, M.D., Ronald G. Pearl, M.D., Ph.D., Stephen Heard, M.D., Robert An, Ph.D.,
Peter J. Bowers, M.D., Paul Burton, M.D., Ph.D., Mark A. Klausner, M.D., Michael J. Corwin, M.D., for the EPO Critical Care Trials Group
N Engl J MedVolume 357(10):965-976
September 6, 2007
![Page 3: Nejmepoetinalfa In Critically Ill Patients(Blue Slide Set)](https://reader035.vdocuments.site/reader035/viewer/2022062613/54559bf9af79595d048b5255/html5/thumbnails/3.jpg)
Hypothesis
Patients with anemia of critical illness often suffer impaired RBC production and an absence of elevated erythropoetin concentrations
Therapy with Recombinant Human Erythropoietin (epoetin alfa) might raise the Hgb Concentrations and reduce the need for red-cell transfusions
![Page 4: Nejmepoetinalfa In Critically Ill Patients(Blue Slide Set)](https://reader035.vdocuments.site/reader035/viewer/2022062613/54559bf9af79595d048b5255/html5/thumbnails/4.jpg)
Methods In this randomized, placebo-controlled
trial, the investigators administered epoetin alfa or placebo to 1460 medical, surgical, or trauma patients between 48 and 96 hours after admission to the intensive care unit
Epoetin alfa (40,000 U) or placebo was administered SC on day 1 and weekly for a maximum 3 weeks, patients were followed for 140 days
![Page 5: Nejmepoetinalfa In Critically Ill Patients(Blue Slide Set)](https://reader035.vdocuments.site/reader035/viewer/2022062613/54559bf9af79595d048b5255/html5/thumbnails/5.jpg)
Primary Endpoint
Percentage of Patients who Received a Red Cell Transfusion
Between Days 1 and 29
![Page 6: Nejmepoetinalfa In Critically Ill Patients(Blue Slide Set)](https://reader035.vdocuments.site/reader035/viewer/2022062613/54559bf9af79595d048b5255/html5/thumbnails/6.jpg)
Secondary Endpoints
• Number of Red Cells Transfused• Mortality• Change in Hemoglobin Concentration
From Baseline
![Page 7: Nejmepoetinalfa In Critically Ill Patients(Blue Slide Set)](https://reader035.vdocuments.site/reader035/viewer/2022062613/54559bf9af79595d048b5255/html5/thumbnails/7.jpg)
Inclusion Criteria
• All Patients Admitted to Medical, Surgical or Medical-Surgical ICU and Remained in the ICU for 2 Days
• Age 18 years or older• Hemoglobin Concentration of Less
than 12g /deciliter• Written Informed Consent
![Page 8: Nejmepoetinalfa In Critically Ill Patients(Blue Slide Set)](https://reader035.vdocuments.site/reader035/viewer/2022062613/54559bf9af79595d048b5255/html5/thumbnails/8.jpg)
Exclusion Criteria
• Expected Discharge from ICU within 48 hours after the 2nd day in ICU
• Acute Ischemic Heart Disease during the ICU stay
• Stay of more than 48 hours duration in the ICU of a tranferring hospital
• Presence of a left ventricular assist device
• History of a pulmonary embolus
• Deep venous thrombosis
• Ischemic stroke
• Dialysis for any indication
• Uncontrolled Hypertension after adequate antihypertensive therapy
• New-onset seizures within the past 3 months
• 3rd degree burns on more than 20% of the body-surface area
![Page 9: Nejmepoetinalfa In Critically Ill Patients(Blue Slide Set)](https://reader035.vdocuments.site/reader035/viewer/2022062613/54559bf9af79595d048b5255/html5/thumbnails/9.jpg)
Exclusions Cont’d
• Pregnancy or Lactation• Diagnosis of Acute clinically significant GI
bleeding on admission• Transfusion at time of planned enrollment• Treatment of epoetin alfa within the past 30
days• Inability or unwillingness to receive blood
products• Participation in another study• Hypersensitivity to epoetin alfa
![Page 10: Nejmepoetinalfa In Critically Ill Patients(Blue Slide Set)](https://reader035.vdocuments.site/reader035/viewer/2022062613/54559bf9af79595d048b5255/html5/thumbnails/10.jpg)
Screening and Enrollment of Study Patients
Corwin HL et al. N Engl J Med 2007;357:965-976
![Page 11: Nejmepoetinalfa In Critically Ill Patients(Blue Slide Set)](https://reader035.vdocuments.site/reader035/viewer/2022062613/54559bf9af79595d048b5255/html5/thumbnails/11.jpg)
Summary of Data on Red-Cell Transfusion
Corwin HL et al. N Engl J Med 2007;357:965-976
![Page 12: Nejmepoetinalfa In Critically Ill Patients(Blue Slide Set)](https://reader035.vdocuments.site/reader035/viewer/2022062613/54559bf9af79595d048b5255/html5/thumbnails/12.jpg)
Hemoglobin Concentration
• Day 29, the increase in the Hgb Concentration from baseline was Greater in the EPO than in Placebo (1.6 vs 1.2 ) g/deciliter
• Day 42, Hgb Concentrations in 2 study groups were not significantly different
[p
![Page 13: Nejmepoetinalfa In Critically Ill Patients(Blue Slide Set)](https://reader035.vdocuments.site/reader035/viewer/2022062613/54559bf9af79595d048b5255/html5/thumbnails/13.jpg)
Mortality at Day 29 and Day 140 in the Intention-to-Treat Population
Corwin HL et al. N Engl J Med 2007;357:965-976
![Page 14: Nejmepoetinalfa In Critically Ill Patients(Blue Slide Set)](https://reader035.vdocuments.site/reader035/viewer/2022062613/54559bf9af79595d048b5255/html5/thumbnails/14.jpg)
Serious Adverse Events
Corwin HL et al. N Engl J Med 2007;357:965-976
![Page 15: Nejmepoetinalfa In Critically Ill Patients(Blue Slide Set)](https://reader035.vdocuments.site/reader035/viewer/2022062613/54559bf9af79595d048b5255/html5/thumbnails/15.jpg)
Conclusions
• Treatment with epoetin alfa did not reduce the percentage of patients receiving a red-cell transfusion (the primary outcome)
• Appeared to reduce mortality in patients with trauma
![Page 16: Nejmepoetinalfa In Critically Ill Patients(Blue Slide Set)](https://reader035.vdocuments.site/reader035/viewer/2022062613/54559bf9af79595d048b5255/html5/thumbnails/16.jpg)
Questions ?
![Page 17: Nejmepoetinalfa In Critically Ill Patients(Blue Slide Set)](https://reader035.vdocuments.site/reader035/viewer/2022062613/54559bf9af79595d048b5255/html5/thumbnails/17.jpg)
THANK YOU